HK1201478A1 - Long-acting glp-1/glucagon receptor agonists glp-1/ - Google Patents

Long-acting glp-1/glucagon receptor agonists glp-1/

Info

Publication number
HK1201478A1
HK1201478A1 HK15102153.2A HK15102153A HK1201478A1 HK 1201478 A1 HK1201478 A1 HK 1201478A1 HK 15102153 A HK15102153 A HK 15102153A HK 1201478 A1 HK1201478 A1 HK 1201478A1
Authority
HK
Hong Kong
Prior art keywords
glp
long
receptor agonists
glucagon receptor
acting
Prior art date
Application number
HK15102153.2A
Other languages
English (en)
Chinese (zh)
Inventor
Udi Eyal Fima
Oren Hershkovitz
Original Assignee
Opko Biolog Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biolog Ltd filed Critical Opko Biolog Ltd
Publication of HK1201478A1 publication Critical patent/HK1201478A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102153.2A 2011-06-02 2015-03-03 Long-acting glp-1/glucagon receptor agonists glp-1/ HK1201478A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492448P 2011-06-02 2011-06-02
US201261624589P 2012-04-16 2012-04-16
PCT/US2012/040744 WO2012167251A1 (en) 2011-06-02 2012-06-04 Long-acting glp-1/glucagon receptor agonists

Publications (1)

Publication Number Publication Date
HK1201478A1 true HK1201478A1 (en) 2015-09-04

Family

ID=47259955

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102153.2A HK1201478A1 (en) 2011-06-02 2015-03-03 Long-acting glp-1/glucagon receptor agonists glp-1/

Country Status (17)

Country Link
US (1) US20140349922A1 (es)
EP (1) EP2714070B1 (es)
JP (1) JP6182134B2 (es)
KR (1) KR102092206B1 (es)
CN (1) CN104023739A (es)
AU (1) AU2012261869B2 (es)
BR (1) BR112013030933A2 (es)
CA (1) CA2837710C (es)
CL (1) CL2013003450A1 (es)
CO (1) CO6980619A2 (es)
EA (1) EA201391764A1 (es)
ES (1) ES2981891T3 (es)
HK (1) HK1201478A1 (es)
IL (1) IL229732B (es)
MX (1) MX346957B (es)
SG (1) SG10201606243YA (es)
WO (1) WO2012167251A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
CN109096387B (zh) * 2012-06-04 2021-11-30 奥普科生物制品有限公司 聚乙二醇化的oxm变体
CN112661863A (zh) 2012-11-20 2021-04-16 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
PE20161153A1 (es) 2014-01-20 2016-10-27 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
MX2017015375A (es) * 2015-05-29 2018-06-19 Opko Biologics Ltd Variantes de oxintomodulina pegilada.
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
TW201706291A (zh) * 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP3368693A4 (en) * 2015-10-30 2019-03-27 The Research Foundation For The State University Of New York University at Buffalo OXYNTOMODULINE ANALOGUES AND METHODS OF PREPARATION AND USE
CN113456820B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
EP3468610A1 (en) * 2016-06-09 2019-04-17 OPKO Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
KR20240006077A (ko) 2016-07-11 2024-01-12 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
CA3054899A1 (en) 2017-03-23 2018-09-27 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
US11376345B2 (en) 2017-11-23 2022-07-05 Sentigel Ab Hydrogel composition and its uses
US20200262887A1 (en) * 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
EP3924369A1 (en) 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
JP5297817B2 (ja) * 2006-02-22 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション オキシントモジュリン誘導体
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
AU2010225523B2 (en) * 2009-03-20 2012-05-24 Hanmi Science Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad

Also Published As

Publication number Publication date
IL229732B (en) 2021-10-31
KR20140083929A (ko) 2014-07-04
CA2837710C (en) 2022-11-08
MX2013014069A (es) 2014-08-22
IL229732A0 (en) 2014-01-30
KR102092206B1 (ko) 2020-03-24
EP2714070A4 (en) 2015-03-04
CN104023739A (zh) 2014-09-03
AU2012261869B2 (en) 2017-01-05
EP2714070A1 (en) 2014-04-09
EP2714070B1 (en) 2024-03-20
EA201391764A1 (ru) 2014-07-30
MX346957B (es) 2017-04-06
JP2014516993A (ja) 2014-07-17
CA2837710A1 (en) 2012-12-06
WO2012167251A1 (en) 2012-12-06
AU2012261869A1 (en) 2014-01-16
CL2013003450A1 (es) 2015-01-16
BR112013030933A2 (pt) 2018-04-24
JP6182134B2 (ja) 2017-08-16
CO6980619A2 (es) 2014-06-27
US20140349922A1 (en) 2014-11-27
SG10201606243YA (en) 2016-09-29
ES2981891T3 (es) 2024-10-11

Similar Documents

Publication Publication Date Title
HK1201478A1 (en) Long-acting glp-1/glucagon receptor agonists glp-1/
HRP20181300T1 (hr) Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
IL230061B (en) Glucagon/1–glp receptor co-agonists
EP2723766A4 (en) COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
AU2012273365A8 (en) Glucagon/GLP-1 receptor co-agonists
ZA201501694B (en) Exendin-4 derivatives as dual glp1/glucagon agonists
HK1202119A1 (en) Novel glp-1 receptor modulators glp-1
AP3338A (en) Glucagon receptor modulator
PL2714661T3 (pl) Pochodne kwasu pikolinamidopropanowego przydatne jako antagoniści receptora glukagonu
PT2714647E (pt) Derivativos bifenil usados como antagonistas do recetor da glicagina